GE11 Peptide as an Active Targeting Agent in Antitumor Therapy: A Minireview

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Solid tumors often exhibit uncontrolled cell growth signaling via receptors like the epidermal growth factor receptor (EGFR).
• Targeting these receptors is crucial for improving the efficacy of chemotherapy.
• Colloidal drug delivery systems can be engineered for targeted cancer therapy.

Purpose of the Study:

• To review recent advancements in targeting the epidermal growth factor receptor (EGFR) using the GE11 peptide.
• To discuss the combination of GE11 peptide with colloidal drug delivery systems for smart antitumor drug delivery.
• To provide insights into active targeting strategies for solid tumors.

Main Methods:

• Review of literature on EGFR structure, function, and the GE11 peptide's biologic activity.
• Analysis of GE11 peptide conjugation techniques to drug delivery systems.
• Discussion of GE11-conjugated colloidal systems, including polymer nanoparticles, as drug carriers.

Main Results:

• The GE11 peptide demonstrates specific binding to EGFR, enabling targeted delivery of therapeutic agents.
• GE11 conjugation to polymer nanoparticles creates effective smart carriers for antitumor drugs.
• Case studies illustrate successful tumor cell targeting using GE11-peptide-conjugated systems.

Conclusions:

• GE11 peptide-mediated EGFR targeting represents a promising strategy for enhancing chemotherapy efficacy in solid tumors.
• Smart colloidal drug delivery systems, particularly polymer nanoparticles, are valuable for targeted cancer therapy.
• Further research in active tumor targeting contributes to developing more effective cancer treatments.